BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:INV-8989 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of INV-8989\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07610798-2553@assetmemo.bio
DTSTAMP:20261121T005429Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:INV-8989: Phase 1/2 readout est. (NCT07610798)
DESCRIPTION:INV-8989\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A St
 udy to Evaluate the Safety\, Tolerability\, Pharmacokinetics\, and Prelimi
 nary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors
  Harboring KRAS G12D Mutations\nEstimated primary completion: May 2029. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/inv-8989#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07610798
URL:https://assetmemo.bio/drug/inv-8989#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
